AMPA receptors as drug targets in neurological disease--advantages, caveats, and future outlook.
Most excitatory transmission in the brain is mediated by the AMPA receptor subtype of the ionotropic glutamate receptors. In many neurological diseases, synapse structure and AMPA receptor function are altered, thus making AMPA receptors potential therapeutic targets for clinical intervention. The work summarized in this review suggests a link between AMPA receptor function and debilitating neuropathologies, and discusses the current state of therapies targeting AMPA receptors in four diseases. In amyotrophic lateral sclerosis, AMPA receptors allow cytotoxic levels of calcium into neurons, leading to motor neuron death. Likewise, in some epilepsies, overactivation of AMPA receptors leads to neuron damage. The same is true for ischemia, where oxygen deprivation leads to excitotoxicity. Conversely, Alzheimer's disease is characterized by decreased AMPA activation and synapse loss. Unfortunately, many clinical studies have had limited success by directly targeting AMPA receptors in these diseases. We also discuss how the use of AMPA receptor modulators, commonly known as ampakines, in neurological diseases initially seemed promising in animal studies, but mostly ineffective in clinical trials. We propose that indirectly affecting AMPA receptors, such as by modulating transmembrane AMPA receptor regulatory proteins or, more generally, by regulating glutamatergic transmission, may provide new therapeutic potential for neurological disorders.
Department of Pharmacology & Therapeutics, McGill University, Montreal, QC, Canada.
Philip K-Y
PK
Chang
David
D
Verbich
R Anne
RA
McKinney
D000544:Alzheimer Disease / Q000188:drug therapy / Q000503:physiopathology; D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy / Q000503:physiopathology; D000818:Animals; D004827:Epilepsy / Q000188:drug therapy / Q000503:physiopathology; D019706:Excitatory Postsynaptic Potentials / Q000187:drug effects; D006801:Humans; D051379:Mice; D058990:Molecular Targeted Therapy / Q000639:trends; D009422:Nervous System Diseases / Q000188:drug therapy*; D018377:Neurotransmitter Agents / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D018091:Receptors, AMPA / Q000819:agonists / Q000037:antagonists & inhibitors* / Q000502:physiology
D018377:Neurotransmitter Agents; D018091:Receptors, AMPA